Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
KRRO Stock Forecast 2025-2026
$33.84
Current Price
$317.79M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to KRRO Price Targets
+431.9%
To High Target of $180.00
+158.6%
To Median Target of $87.50
-26.1%
To Low Target of $25.00
KRRO Price Momentum
-17.3%
1 Week Change
-27.6%
1 Month Change
-51.9%
1 Year Change
-11.1%
Year-to-Date Change
-55.9%
From 52W High of $76.79
+228.9%
From 52W Low of $10.29
📊 TOP ANALYST CALLS
Did KRRO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Korro Bio is one of their latest high-conviction picks.
Latest KRRO Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, KRRO has a bullish consensus with a median price target of $87.50 (ranging from $25.00 to $180.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $33.84, the median forecast implies a 158.6% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 431.9% upside. Conversely, the most conservative target is provided by Keay Nakae at Chardan Capital, suggesting a 26.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KRRO Analyst Ratings
9
Buy
0
Hold
0
Sell
KRRO Price Target Range
Low
$25.00
Average
$87.50
High
$180.00
Current: $33.84
Latest KRRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KRRO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2025 | Clear Street | Bill Maughan | Buy | Initiates | $93.00 |
| Aug 13, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $90.00 |
| Aug 13, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $25.00 |
| Aug 13, 2025 | Raymond James | Steven Seedhouse | Strong Buy | Maintains | $147.00 |
| Jul 24, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
| May 13, 2025 | Oppenheimer | Andreas Argyrides | Outperform | Maintains | $90.00 |
| May 13, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $25.00 |
| May 8, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $100.00 |
| Apr 29, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Initiates | $74.00 |
| Apr 16, 2025 | Chardan Capital | Keay Nakae | Buy | Initiates | $25.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
| Mar 19, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $95.00 |
| Nov 22, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
| Nov 18, 2024 | Jones Trading | Catherine Novack | Buy | Initiates | $130.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
| Oct 21, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Initiates | $153.00 |
| Oct 21, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $105.00 |
| Oct 18, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $115.00 |
| Sep 19, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $95.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
Korro Bio Inc. (KRRO) Competitors
The following stocks are similar to Korro Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Korro Bio Inc. (KRRO) Financial Data
Korro Bio Inc. has a market capitalization of $317.79M with a P/E ratio of -3.6x. The company generates $6.28M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -42.7% quarter-over-quarter, while maintaining an operating margin of -1,863.2% and return on equity of -58.3%.
Valuation Metrics
Market Cap
$317.79M
Enterprise Value
$294.04M
P/E Ratio
-3.6x
PEG Ratio
-0.3x
Price/Sales
48.7x
Growth & Margins
Revenue Growth (YoY)
-42.7%
Gross Margin
N/A
Operating Margin
-1,863.2%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+30.3%
Current Ratio
6.0x
Debt/Equity
38.8x
ROE
-58.3%
ROA
-28.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Korro Bio Inc. (KRRO) Business Model
About Korro Bio Inc.
What They Do
Develops innovative RNA editing therapies.
Business Model
Korro Bio Inc. operates in the biotechnology sector, focusing on RNA editing to develop therapies that correct genetic mutations. The company generates revenue through the research and development of advanced genetic treatments aimed at addressing genetic disorders and diseases.
Additional Information
Positioned at the forefront of genetic research and personalized medicine, Korro Bio Inc. is a significant player in the biotech field. Its commitment to innovation and transformative healthcare solutions makes it an important company to watch for investors interested in the advancements of genomic technologies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
92
CEO
Dr. Ram Aiyar MBA, Ph.D.
Country
United States
IPO Year
2019
Website
www.korrobio.comKorro Bio Inc. (KRRO) Latest News & Analysis
Latest News
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) will participate in several investor and scientific conferences in September 2025, as announced by the company on September 2, 2025.
Why It Matters
Korro Bio's participation in investor and scientific conferences signals potential updates on its developments, which could affect stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. reported that its Phase 1/2a REWRITE trial for KRRO-110 is on schedule for a mid-2025 readout. The EMA granted Orphan Drug Designation for KRRO-110, and the company ended Q2 2025 with $119.6 million in cash.
Why It Matters
Korro Bio's trial progress and EMA's Orphan Drug Designation position it favorably for investors, indicating potential market value and reduced regulatory hurdles for KRRO-110.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) received orphan drug designation from the EMA for KRRO-110, its investigational treatment for Alpha-1 Antitrypsin Deficiency, supporting its genetic medicine development.
Why It Matters
Korro Bio's orphan drug designation for KRRO-110 enhances its market potential and attractiveness, potentially leading to increased investment interest and share price appreciation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) will participate in the 2025 RBC Capital Markets Global Healthcare Conference, with management member Ram Aiyar, Ph.D. presenting.
Why It Matters
Korro Bio's participation in investor conferences signals potential growth and investor engagement, which could affect stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Korro Bio, Inc. (Nasdaq: KRRO) reported its Q1 2025 financial results and provided a business update. The company focuses on RNA editing for genetic medicines targeting various diseases.
Why It Matters
Korro Bio's Q1 2025 results and business update signal its progress in RNA editing, which could impact future revenue, investor sentiment, and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
7 months ago
Quick Summary
The company has appointed GaoZhong Zhu, Ph.D. as Senior VP of Chemistry, Manufacturing and Controls, and promoted Oliver Dolan to Principal Accounting Officer, enhancing its leadership team.
Why It Matters
Key leadership appointments can enhance a company's strategic direction and operational efficiency, potentially leading to improved performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About KRRO Stock
What is Korro Bio Inc.'s (KRRO) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Korro Bio Inc. (KRRO) has a median price target of $87.50. The highest price target is $180.00 and the lowest is $25.00.
Is KRRO stock a good investment in 2026?
According to current analyst ratings, KRRO has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $33.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for KRRO stock?
Wall Street analysts predict KRRO stock could reach $87.50 in the next 12 months. This represents a 158.6% increase from the current price of $33.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Korro Bio Inc.'s business model?
Korro Bio Inc. operates in the biotechnology sector, focusing on RNA editing to develop therapies that correct genetic mutations. The company generates revenue through the research and development of advanced genetic treatments aimed at addressing genetic disorders and diseases.
What is the highest forecasted price for KRRO Korro Bio Inc.?
The highest price target for KRRO is $180.00 from Yasmeen Rahimi at Piper Sandler, which represents a 431.9% increase from the current price of $33.84.
What is the lowest forecasted price for KRRO Korro Bio Inc.?
The lowest price target for KRRO is $25.00 from Keay Nakae at Chardan Capital, which represents a -26.1% decrease from the current price of $33.84.
What is the overall KRRO consensus from analysts for Korro Bio Inc.?
The overall analyst consensus for KRRO is bullish. Out of 12 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $87.50.
How accurate are KRRO stock price projections?
Stock price projections, including those for Korro Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 1:29 PM UTC